Related Experiment Videos
Hypertension in bone marrow transplanted patients.
Acta Clinica Belgica
|January 1, 1989
Summary
Cyclosporine (CyA) can cause hypertension in bone marrow transplant patients. This study found that the hypertension is linked to kidney impairment, not the renin-angiotensin system.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Cyclosporine (CyA) is a crucial immunosuppressant used in bone marrow transplantation (BMT).
- Hypertension is a known complication of CyA therapy, but its underlying mechanisms require further elucidation.
Purpose of the Study:
- To investigate the etiological factors of cyclosporine-induced hypertension in bone marrow transplant patients.
- To differentiate between renal and renin-angiotensin system involvement in CyA-induced hypertension.
Main Methods:
- Prospective study of 10 BMT patients, monitoring blood pressure, plasma renin activity, and serum creatinine.
- Measurements taken one week before and three weeks after CyA administration.
- Comparison between hypertensive and normotensive patient groups.
Main Results:
- Four out of ten patients developed significant hypertension post-CyA administration.
- Hypertensive patients showed significantly lower plasma renin activity and a significant rise in serum creatinine compared to normotensive patients.
- Serum creatinine increase correlated with blood pressure elevation, while body weight and 6-keto PGF1 alpha levels remained unchanged.
Conclusions:
- Cyclosporine-induced hypertension in BMT patients is common.
- Hypertension is primarily associated with renal impairment rather than the renin-angiotensin axis.
- Monitoring renal function is crucial in BMT patients receiving cyclosporine.